Sino Biopharmaceutical’s TDI01 Gains Breakthrough Therapy Designation

Sino Biopharmaceutical ( (HK:1177) ) has shared an announcement.

Sino Biopharmaceutical Limited announced that its self-developed Class 1 innovative drug, TDI01 suspension, has been included in the Breakthrough Therapy Designation process by China’s Center for Drug Evaluation. TDI01, a ROCK2 inhibitor, has shown significant efficacy and safety in treating moderate to severe chronic graft-versus-host disease (cGVHD) and is also being trialed for other conditions like idiopathic pulmonary fibrosis. This advancement underscores the company’s commitment to providing innovative treatment options and may enhance its position in the pharmaceutical industry.

The most recent analyst rating on (HK:1177) stock is a Buy with a HK$7.00 price target. To see the full list of analyst forecasts on Sino Biopharmaceutical stock, see the HK:1177 Stock Forecast page.

More about Sino Biopharmaceutical

Sino Biopharmaceutical Limited is a company incorporated in the Cayman Islands, operating in the pharmaceutical industry. It focuses on the development and commercialization of innovative drugs, particularly in the field of biopharmaceuticals.

YTD Price Performance: 72.81%

Average Trading Volume: 125,512,696

Technical Sentiment Signal: Buy

Current Market Cap: HK$98.9B

See more data about 1177 stock on TipRanks’ Stock Analysis page.